Physician profile
Michael R Oreilly
NPI 1891723995
$2,793.60
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $313 · 2021: $497 · 2022: $1,381 · 2023: $59.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $59.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $59.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $678.80 | 2019-2023 | |
| Exeltis, USA INC. | $528.08 | 2019-2022 | |
| Agile Therapeutics, INC. | $174.67 | 2021-2022 | |
| Therapeuticsmd, INC. | $167.51 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $159.20 | 2019-2022 | |
| Avion Pharmaceuticals | $158.72 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $114.04 | 2021-2022 | |
| Evofem Biosciences, INC. | $99.17 | 2021-2022 | |
| Lupin INC. | $87.21 | 2019-2021 | |
| Organon LLC | $66.28 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $66.04 | 2019-2020 | |
| Medtronic Vascular, INC. | $60.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.93 | 2022 | |
| Merck Sharp & Dohme LLC | $53.69 | 2019-2022 | |
| Pfizer INC. | $50.60 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $38.40 | 2019 | |
| Myovant Sciences INC. | $37.53 | 2021-2022 | |
| Allergan, INC. | $37.12 | 2019 | |
| Amag Pharmaceuticals, INC. | $36.97 | 2019 | |
| Vertical Pharmaceuticals, LLC | $32.99 | 2019 | |
| Astellas Pharma US INC | $31.02 | 2020 | |
| Sumitomo Pharma America, INC. | $25.23 | 2023 | Myfembree |
| Urovant Sciences INC | $17.51 | 2022 | |
| Mylan Pharmaceuticals INC. | $12.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Oreilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.